Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 530
- Registration Number
- NCT00138567
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
🇩🇪Novartis Investigative site, Investigative Centers, Germany
Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 478
- Registration Number
- NCT00138619
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
- Conditions
- Wet Age-Related Macular Degeneration
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 50
- Registration Number
- NCT00138632
- Locations
- 🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Porter Adventist Hospital, Eye Lab, Denver, Colorado, United States
🇺🇸USF Eye Institute, Tampa, Florida, United States
Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 440
- Registration Number
- NCT00138541
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 318
- Registration Number
- NCT00138554
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 418
- Registration Number
- NCT00138515
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia
- Conditions
- Mixed DyslipidemiaHypercholesterolemia
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 325
- Registration Number
- NCT00136799
- Locations
- 🇨🇳
Novartis, Shangai, China
Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus
- Conditions
- Albuminuria
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2011-03-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 332
- Registration Number
- NCT00136773
Photodynamic Therapy in Occult-Only Lesions (POOL)
- Conditions
- Age-Related Macular Degeneration
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2006-06-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 202
- Registration Number
- NCT00135837
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Local Tolerability and Safety of Povidone K25 Eye Drops (Artificial Tears Containing Povidone) Versus Placebo in Healthy Volunteers
- Conditions
- Healthy
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00135824
- Locations
- 🇩🇪
Novartis Investigational Site, Heidelberg, Germany